CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Should l Buy ?
Source: Globenewswire
Financial Performance: CytoMed Therapeutics reported a reduced net loss of US$1.85 million for the year ending December 31, 2024, an improvement from US$3.03 million in 2023, with cash balances of US$3.64 million and plans for strategic growth in cellular immunotherapy targeting cancers and autoimmune diseases.
Clinical Developments: The company is advancing its clinical trials, including the ANGELICA trial for CAR T therapy using gamma delta T cells, and plans to expand operations in Malaysia and India while exploring partnerships in China to enhance its manufacturing capabilities and reach more patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
